Un compuesto natural dirigido a PCID2 suprime la progresión del carcinoma hepatocelular: evidencia del descubrimiento...

Área de la Ciencia:

• Oncology
• Pharmacology
• Natural Products Chemistry

Sus antecedentes:

• Hepatocellular carcinoma (HCC) is a deadly cancer with few treatment options.
• PCID2 (PCI-domain containing protein 2) is a potential therapeutic target for HCC, but specific inhibitors are lacking.
• Traditional Chinese Medicine (TCM) offers a rich source of novel anticancer compounds.

Objetivo del estudio:

• To identify novel small molecules targeting PCID2 for HCC treatment.
• To investigate the anti-cancer effects and mechanisms of 1,2,3,4,6-Penta-O-galloyl--D-glucose (-PGG) against HCC.

Principales métodos:

• Molecular docking was used to screen TCM-derived compounds for PCID2 targeting.
• Surface plasmon resonance (SPR) validated the binding of -PGG to PCID2.
• In vitro assays assessed -PGG's effects on HCC cell proliferation, migration, invasion, apoptosis, and cell cycle, with Western blotting for mechanism exploration.

Principales resultados:

• Molecular docking identified -PGG as a potent PCID2 inhibitor; SPR confirmed direct binding.
• -PGG significantly inhibited HCC cell proliferation, migration, and invasion.
• -PGG induced apoptosis and cell cycle arrest, downregulating PCID2, Cyclin D1, CDK6, and suppressing PI3K/Akt phosphorylation.

Conclusiones:

• -PGG demonstrates significant anti-HCC activity by targeting PCID2 and modulating key signaling pathways.
• -PGG is a promising lead compound for HCC therapy, validating PCID2 as a therapeutic target.
• This study highlights the potential of TCM-derived compounds in discovering novel liver cancer treatments.